G Bernhard Landwehrmeyer

List of Publications by Year
in descending order

175 papers	12,891 citations	31902 53 h-index	28224 105 g-index
185 all docs	185 docs citations	185 times ranked	11739 citing authors

#	Article	IF	Citations
1	Genetic modifiers of Huntington disease differentially influence motor and cognitive domains. American Journal of Human Genetics, 2022, 109, 885-899.	2.6	29
2	Exome sequencing of individuals with Huntingtonâ€™s disease implicates FAN1 nuclease activity in slowing CAG expansion and disease onset. Nature Neuroscience, 2022, 25, 446-457.	7.1	31
3	241â€... Intrathecal antisense oligonucleotide delivery in HD: experience from RG6042 programme and best practice considerations. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A83.1-A83.	0.9	0
4	Cerebrospinal Fluid Levels of Prodynorphinâ€Derived Peptides are Decreased in Huntington's Disease. Movement Disorders, 2021, 36, 492-497.	2.2	12
5	Ubiquitination and the proteasome rather than caspaseâ€3â€mediated Câ€terminal cleavage are involved in the EAAT2 degradation by staurosporineâ€induced cellular stress. Journal of Neurochemistry, 2021, 157, 1284-1299.	2.1	4
6	Quantifying progression in primary progressive aphasia with structural neuroimaging. Alzheimer's and Dementia, 2021, 17, 1595-1609.	0.4	22
7	Research priorities for rare neurological diseases: a representative view of patient representatives and healthcare professionals from the European Reference Network for Rare Neurological Diseases. Orphanet Journal of Rare Diseases, 2021, 16, 135.	1.2	5
8	Timing and Impact of Psychiatric, Cognitive, and Motor Abnormalities in Huntington Disease. Neurology, 2021, 96, e2395-e2406.	1.5	53
9	Validating Automated Segmentation Tools in the Assessment of Caudate Atrophy in Huntingtonâ€™s Disease. Frontiers in Neurology, 2021, 12, 616272.	1.1	3
10	The differential diagnostic value of a battery of oculomotor evaluation in Parkinson's Disease and Multiple System Atrophy. Brain and Behavior, 2021, 11, e02184.	1.0	13
11	Monitoring the Motor Phenotype in Huntingtonâ€™s Disease by Analysis of Keyboard Typing During Real Life Computer Use. Journal of Huntington's Disease, 2021, 10, 259-268.	0.9	7
12	Motor speech disorders in the nonfluent, semantic and logopenic variants of primary progressive aphasia. Cortex, 2021, 140, 66-79.	1.1	10
13	How to Arrange Follow-Up Time-Intervals for Longitudinal Brain MRI Studies in Neurodegenerative Diseases. Frontiers in Neuroscience, 2021, 15, 682812.	1.4	3
14	Effect of Body Weight on Age at Onset in Huntington Disease. Neurology: Genetics, 2021, 7, e603.	0.9	7
15	Enroll-HD: An Integrated Clinical Research Platform and Worldwide Observational Study for Huntington's Disease. Frontiers in Neurology, 2021, 12, 667420.	1.1	31
16	A07â€...Huntingtin-dependent stability of HAP40 and decreased HAP40 levels in huntingtonâ€™s disease. , 2021, , .		0
17	F36â€...DXA, BIA, anthropometry and skin folds methodology in body composition. , 2021, , .		0
18	HAP40 protein levels are huntingtin-dependent and decrease in Huntington disease. Neurobiology of Disease, 2021, 158, 105476.	2.1	7

#	Article	IF	Citations
19	Clinico-genetic findings in 509 frontotemporal dementia patients. Molecular Psychiatry, 2021, 26, 5824-5832.	4.1	23
20	Predicting disease progression in behavioral variant frontotemporal dementia. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12262.	1.2	4
21	Factors influencing atrophy progression in primary progressive aphasia. Alzheimer's and Dementia, 2021, 17, .	0.4	0
22	Genetic Risk Underlying Psychiatric and Cognitive Symptoms in Huntingtonâ€™s Disease. Biological Psychiatry, 2020, 87, 857-865.	0.7	29
23	Different CSF protein profiles in amyotrophic lateral sclerosis and frontotemporal dementia with C9orf72 hexanucleotide repeat expansion. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 503-511.	0.9	33
24	PET Molecular Imaging of Phosphodiesterase 10A: An Early Biomarker of Huntington's Disease Progression. Movement Disorders, 2020, 35, 606-615.	2.2	25
25	The European Reference Network for Rare Neurological Diseases. Frontiers in Neurology, 2020, 11, 616569.	1.1	26
26	CAG Repeat Not Polyglutamine Length Determines Timing of Huntingtonâ€™s Disease Onset. Cell, 2019, 178, 887-900.e14.	13.5	301
27	Association of CAG Repeats With Long-term Progression in Huntington Disease. JAMA Neurology, 2019, 76, 1375.	4.5	44
28	An International Validation of a Clinical Tool to Assess Carersâ€™ Quality of Life in Huntingtonâ€™s Disease. Frontiers in Psychology, 2019, 10, 1658.	1.1	2
29	Olfactory screening of Parkinsonâ€™s Disease patients and healthy subjects in China and Germany: A study of cross-cultural adaptation of the Sniffinâ€™ Sticks 12-identification test. PLoS ONE, 2019, 14, e0224331.	1.1	14
30	FDG-PET underscores the key role of the thalamus in frontotemporal lobar degeneration caused by C9ORF72 mutations. Translational Psychiatry, 2019, 9, 54.	2.4	28
31	MSH3 modifies somatic instability and disease severity in Huntingtonâ€™s and myotonic dystrophy type 1. Brain, 2019, 142, 1876-1886.	3.7	114
32	Movement Disorder Society Task Force Viewpoint: Huntington's Disease Diagnostic Categories. Movement Disorders Clinical Practice, 2019, 6, 541-546.	0.8	67
33	Meaningful and Measurable Health Domains in Huntingtonâ€™s Disease: Large-Scale Validation of the Huntingtonâ€™s Disease Health-Related Quality of Life Questionnaire Across Severity Stages. Value in Health, 2019, 22, 712-720.	0.1	6
34	Targeting Huntingtin Expression in Patients with Huntingtonâ€™s Disease. New England Journal of Medicine, 2019, 380, 2307-2316.	13.9	493
35	Unraveling corticobasal syndrome and alien limb syndrome with structural brain imaging. Cortex, 2019, 117, 33-40.	1.1	17
36	Defining pediatric huntington disease: Time to abandon the term Juvenile Huntington Disease?. Movement Disorders, 2019, 34, 584-585.	2.2	16

#	Article	IF	Citations
37	Identification of symbol digit modality test score extremes in Huntington's disease. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2019, 180, 232-245.	1.1	13
38	Combined cerebral atrophy score in Huntington's disease based on atlas-based MRI volumetry: Sample size calculations for clinical trials. Parkinsonism and Related Disorders, 2019, 63, 179-184.	1.1	12
39	Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study. Lancet Neurology, The, 2019, 18, 165-176.	4.9	82
40	Title is missing!. , 2019, 14, e0224331.		0
41	Title is missing!. , 2019, 14, e0224331.		0
42	Title is missing!. , 2019, 14, e0224331.		0
43	Title is missing!. , 2019, 14, e0224331.		0
44	Objective assessment of gait and posture in premanifest and manifest Huntington disease â€" A multi-center study. Gait and Posture, 2018, 62, 451-457.	0.6	18
45	The contribution of gender differences in motor, behavioral and cognitive features to functional capacity, independence and quality of life in patients with Huntington's disease. Parkinsonism and Related Disorders, 2018, 49, 42-47.	1.1	46
46	A language-based sum score for the course and therapeutic intervention in primary progressive aphasia. Alzheimer's Research and Therapy, 2018, 10, 41.	3.0	8
47	Suicidal ideation and suicidal behavior according to the C-SSRS in a European cohort of Huntington's disease gene expansion carriers. Journal of Affective Disorders, 2018, 228, 194-204.	2.0	20
48	Chitotriosidase (CHIT1) is increased in microglia and macrophages in spinal cord of amyotrophic lateral sclerosis and cerebrospinal fluid levels correlate with disease severity and progression. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 239-247.	0.9	89
49	F13â€...Assessment of the performance of a modified motor scale as applied to juvenile onset huntingtonâ€™s disease. , 2018, , .		0
50	F25â€...Huntingtonâ€™s disease health-related quality of life questionnaire (HDQOL): further validation. , 2018, , .		1
51	A34â€...Mitochondrial respiration is limited by atp-production in the skeletal muscle of the R6/2 hd mouse model. , 2018, , .		0
52	Serum neurofilament light chain in behavioral variant frontotemporal dementia. Neurology, 2018, 91, e1390-e1401.	1.5	85
53	Biological and clinical manifestations of juvenile Huntington's disease: a retrospective analysis. Lancet Neurology, The, 2018, 17, 986-993.	4.9	115
54	Specific serum and CSF microRNA profiles distinguish sporadic behavioural variant of frontotemporal dementia compared with Alzheimer patients and cognitively healthy controls. PLoS ONE, 2018, 13, e0197329.	1.1	68

#	Article	IF	Citations
55	Atrophy in the Thalamus But Not Cerebellum Is Specific for C9orf72 FTD and ALS Patients â€“ An Atlas-Based Volumetric MRI Study. Frontiers in Aging Neuroscience, 2018, 10, 45.	1.7	40
56	Overlap between age-at-onset and disease-progression determinants in Huntington disease. Neurology, 2018, 90, e2099-e2106.	1.5	32
57	J01â€...Effects of IONIS-HTTRX (RG6042) in patients with early huntingtonâ€™s disease, results of the first htt-lowering drug trial. , 2018, , .		2
58	F49â€...Machine learning approach in analysis of enroll-hd data for suicidality prediction in huntington disease. , 2018, , .		0
59	Predicting primary progressive aphasias with support vector machine approaches in structural MRI data. NeuroImage: Clinical, 2017, 14, 334-343.	1.4	42
60	Neurofilament as a blood marker for diagnosis and monitoring of primary progressive aphasias. Neurology, 2017, 88, 961-969.	1.5	73
61	Polyâ€<scp>GP</scp> in cerebrospinal fluid links C9orf72â€associated dipeptide repeat expression to the asymptomatic phase of <scp>ALS</scp>/<scp>FTD</scp>. EMBO Molecular Medicine, 2017, 9, 859-868.	3.3	90
62	A randomized exploratory phase 2 study in patients with chemotherapy-related peripheral neuropathy evaluating whole-body vibration training as adjunct to an integrated program including massage, passive mobilization and physical exercises. Experimental Hematology and Oncology, 2017, 6, 5.	2.0	43
63	Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study. Lancet Neurology, The, 2017, 16, 701-711.	4.9	248
64	Intact sensory-motor network structure and function in far from onset premanifest Huntingtonâ€™s disease. Scientific Reports, 2017, 7, 43841.	1.6	11
65	Patterns of age related changes for phosphodiesterase type-10A in comparison with dopamine D 2/3 receptors and sub-cortical volumes in the human basal ganglia: A PET study with 18 F-MNI-659 and 11 C-raclopride with correction for partial volume effect. NeuroImage, 2017, 152, 330-339.	2.1	24
66	Survival End Points for Huntington Disease Trials Prior to a Motor Diagnosis. JAMA Neurology, 2017, 74, 1352.	4.5	12
67	Body weight is a robust predictor of clinical progression in Huntington disease. Annals of Neurology, 2017, 82, 479-483.	2.8	67
68	Identification of extreme motor phenotypes in Huntington's disease. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2017, 174, 283-294.	1.1	9
69	Bupropion for the treatment of apathy in Huntingtonâ€™s disease: A multicenter, randomised, double-blind, placebo-controlled, prospective crossover trial. PLoS ONE, 2017, 12, e0173872.	1.1	43
70	High-resolution respirometry of fine-needle muscle biopsies in pre-manifest Huntingtonâ€™s disease expansion mutation carriers shows normal mitochondrial respiratory function. PLoS ONE, 2017, 12, e0175248.	1.1	11
71	Revisiting the Logan plot to account for non-negligible blood volume in brain tissue. EJNMMI Research, 2017, 7, 66.	1.1	8
72	Eighth International Chorea-Acanthocytosis Symposium: Summary of Workshop Discussion and Action Points. Tremor and Other Hyperkinetic Movements, 2017, 7, 428.	1.1	2

#	Article	IF	Citations
73	B30â€…Integrated mitochondrial function in human fine-needle muscle biopsies of huntingtonâ€™s disease mutation carriers and in tissues of HdhQ111 mice. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A19.3-A20.	0.9	0
74	M3â€…Study participation but not the antidepressant bupropion reduces apathy in huntingtonâ€™s disease. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A102.1-A102.	0.9	0
75	I32â€…Using the global clinical research platform of enroll-hd to facilitate the enrollment of premanifest huntington disease (HD) participants in clinical trials. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A70.1-A70.	0.9	0
76	Fast-to-Slow Transition of Skeletal Muscle Contractile Function and Corresponding Changes in Myosin Heavy and Light Chain Formation in the R6/2 Mouse Model of Huntingtonâ€™s Disease. PLoS ONE, 2016, 11, e0166106.	1.1	15
77	I9â€…The size of the CAG-expansion mutation can be predicted in hd based on phenotypic data using a machine learning approach. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A62.1-A62.	0.9	2
78	Atrophy and structural covariance of the cholinergic basal forebrain in primary progressive aphasia. Cortex, 2016, 83, 124-135.	1.1	21
79	Natural variation in sensoryâ€motor white matter organization influences manifestations of Huntington's disease. Human Brain Mapping, 2016, 37, 4615-4628.	1.9	18
80	Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. Nature Genetics, 2016, 48, 1043-1048.	9.4	494
81	The neuropsychology of first impressions: Evidence from Huntington's disease. Cortex, 2016, 85, 100-115.	1.1	21
82	D22â€…Compensation in preclinical huntingtonâ€™s disease: evidence from the track-on HD study. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A42.2-A42.	0.9	0
83	Motor network structure and function are associated with motor performance in Huntingtonâ€™s disease. Journal of Neurology, 2016, 263, 539-549.	1.8	30
84	Neuropsychiatric symptoms are very common in premanifest and early stage Huntington's Disease. Parkinsonism and Related Disorders, 2016, 25, 58-64.	1.1	122
85	Medication Use in Early-HD Participants in Track-HD: an Investigation of its Effects on Clinical Performance. PLOS Currents, 2016, 8, .	1.4	6
86	Longitudinal Diffusion Tensor Imaging Shows Progressive Changes in White Matter in Huntingtonâ€™s Disease. Journal of Huntington's Disease, 2015, 4, 333-346.	0.9	31
87	Compensation in Preclinical Huntington's Disease: Evidence From the Track-On HD Study. EBioMedicine, 2015, 2, 1420-1429.	2.7	122
88	Ethyl-eicosapentaenoic acid treatment in Huntington's disease: A placebo-controlled clinical trial. Movement Disorders, 2015, 30, 1426-1429.	2.2	33
89	A randomized, placeboâ€controlled trial of AFQ056 for the treatment of chorea in Huntington's disease. Movement Disorders, 2015, 30, 427-431.	2.2	67
90	Update on Huntington's disease: Advances in care and emerging therapeutic options. Parkinsonism and Related Disorders, 2015, 21, 169-178.	1.1	61

#	Article	IF	Citations
91	An exploratory doubleâ€blind, randomized clinical trial with selisistat, a <scp>SirT1</scp> inhibitor, in patients with <scp>H</scp>untington's disease. British Journal of Clinical Pharmacology, 2015, 79, 465-476.	1.1	128
92	Abnormal cerebellar volume and corticocerebellar dysfunction in early manifest Huntingtonâ€™s disease. Journal of Neurology, 2015, 262, 859-869.	1.8	39
93	Selective vulnerability of Rich Club brain regions is an organizational principle of structural connectivity loss in Huntingtonâ€™s disease. Brain, 2015, 138, 3327-3344.	3.7	96
94	Short-interval observational data to inform clinical trial design in Huntington's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 1291-1298.	0.9	22
95	Two-Point Magnitude MRI for Rapid Mapping of Brown Adipose Tissue and Its Application to the R6/2 Mouse Model of Huntington Disease. PLoS ONE, 2014, 9, e105556.	1.1	15
96	Cerebellar abnormalities in Huntington's disease: A role in motor and psychiatric impairment?. Movement Disorders, 2014, 29, 1648-1654.	2.2	45
97	Visual system integrity and cognition in early Huntington's disease. European Journal of Neuroscience, 2014, 40, 2417-2426.	1.2	40
98	The neuroanatomy of subthreshold depressive symptoms in Huntington's disease: a combined diffusion tensor imaging (DTI) and voxel-based morphometry (VBM) study. Psychological Medicine, 2014, 44, 1867-1878.	2.7	43
99	Impact of the control for corrupted diffusion tensor imaging data in comparisons at the group level: an application in Huntington disease. BioMedical Engineering OnLine, 2014, 13, 128.	1.3	11
100	A single nucleotide polymorphism in the coding region of PGC-1Î± is a male-specific modifier of Huntington disease age-at-onset in a large European cohort. BMC Neurology, 2014, 14, 1.	0.8	137
101	Neuropsychiatric symptoms in a European Huntington's disease cohort (REGISTRY). Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 1411-1418.	0.9	237
102	Altered Ca2+ signaling in skeletal muscle fibers of the R6/2 mouse, a model of Huntingtonâ€™s disease. Journal of General Physiology, 2014, 144, 393-413.	0.9	27
103	Longitudinal task-negative network analyses in preclinical Huntingtonâ€™s disease. European Archives of Psychiatry and Clinical Neuroscience, 2014, 264, 493-505.	1.8	17
104	The influence of gender on phenotype and disease progression in patients with Huntington's disease. Parkinsonism and Related Disorders, 2013, 19, 192-197.	1.1	96
105	The personal experience of parenting a child with Juvenile Huntingtonâ€™s Disease: perceptions across Europe. European Journal of Human Genetics, 2013, 21, 1042-1048.	1.4	19
106	Evaluating multicenter DTI data in Huntington's disease on site specific effects: An ex post facto approach. NeuroImage: Clinical, 2013, 2, 161-167.	1.4	28
107	Evaluation of multi-modal, multi-site neuroimaging measures in Huntington's disease: Baseline results from the PADDINGTON study. NeuroImage: Clinical, 2013, 2, 204-211.	1.4	34
108	Suicidal ideation in a European Huntington's disease population. Journal of Affective Disorders, 2013, 151, 248-258.	2.0	74

#	Article	IF	Citations
109	Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data. Lancet Neurology, The, 2013, 12, 637-649.	4.9	704
110	Association between caffeine intake and age at onset in Huntington's disease. Neurobiology of Disease, 2013, 58, 179-182.	2.1	63
111	One-year safety and tolerability profile of pridopidine in patients with Huntington disease. Neurology, 2013, 80, 1086-1094.	1.5	19
112	Corpus Callosal Atrophy in Premanifest and Early Huntington's Disease. Journal of Huntington's Disease, 2013, 2, 517-526.	0.9	29
113	Brain Structure in Preclinical Huntington's Disease: A Multi-Method Approach. Neurodegenerative Diseases, 2013, 12, 13-22.	0.8	21
114	Discrepancies in reporting the CAG repeat lengths for Huntington's disease. European Journal of Human Genetics, 2012, 20, 20-26.	1.4	20
115	Interview: Following a standard of care for Huntingtonâ€™s disease. Neurodegenerative Disease Management, 2012, 2, 159-163.	1.2	0
116	Huntington's disease: new aspects on phenotype and genotype. Parkinsonism and Related Disorders, 2012, 18, S107-S109.	1.1	9
117	Default-mode network changes in preclinical Huntington's disease. Experimental Neurology, 2012, 237, 191-198.	2.0	64
118	A greatly extended PPARGC1A genomic locus encodes several new brain-specific isoforms and influences Huntington disease age of onsetâ€. Human Molecular Genetics, 2012, 21, 3461-3473.	1.4	85
119	TAA repeat variation in the GRIK2 gene does not influence age at onset in Huntingtonâ€™s disease. Biochemical and Biophysical Research Communications, 2012, 424, 404-408.	1.0	20
120	Brain activation and functional connectivity in premanifest Huntington's disease during states of intrinsic and phasic alertness. Human Brain Mapping, 2012, 33, 2161-2173.	1.9	49
121	Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data. Lancet Neurology, The, 2012, 11, 42-53.	4.9	479
122	Rate of change in early Huntington's disease: A clinicometric analysis. Movement Disorders, 2012, 27, 118-124.	2.2	34
123	Current Pharmacological Management in Juvenile Huntingtonâ€™s Disease. PLOS Currents, 2012, 4, RRN1304.	1.4	9
124	Magnetic resonance perfusion imaging of resting-state cerebral blood flow in preclinical Huntington's disease. Journal of Cerebral Blood Flow and Metabolism, 2011, 31, 1908-1918.	2.4	54
125	Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurology, The, 2011, 10, 31-42.	4.9	530
126	Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurology, The, 2011, 10, 1049-1057.	4.9	157

#	Article	IF	Citations
127	Longitudinal functional magnetic resonance imaging of cognition in preclinical Huntington's disease. Experimental Neurology, 2011, 231, 214-222.	2.0	45
128	What is the impact of education on Huntington's disease?. Movement Disorders, 2011, 26, 1489-1495.	2.2	34
129	Discriminant Analysis of Beck Depression Inventory and Hamilton Rating Scale for Depression in Huntington's Disease. Journal of Neuropsychiatry and Clinical Neurosciences, 2011, 23, 399-402.	0.9	22
130	Factor analysis of behavioural symptoms in Huntington's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 411-412.	0.9	38
131	Utilisation of Healthcare and Associated Services in Huntingtonâ€™s disease: a data mining study. PLOS Currents, 2011, 3, RRN1206.	1.4	16
132	Assessment of Motor Symptoms and Functional Impact in Prodromal and Early Huntington Disease. PLOS Currents, 2011, 2, RRN1244.	1.4	10
133	NMDA receptor gene variations as modifiers in Huntington disease: a replication study. PLOS Currents, 2011, 3, RRN1247.	1.4	20
134	Stability effects on results of diffusion tensor imaging analysis by reduction of the number of gradient directions due to motion artifacts: an application to presymptomatic Huntingtonâ€™s disease. PLOS Currents, 2011, 3, RRN1292.	1.4	19
135	Caudate Nucleus and Insular Activation During a Pain Suppression Paradigm Comparing Thermal and Electrical Stimulation. Open Neuroimaging Journal, 2011, 5, 1-8.	0.2	37
136	Differential pattern of brainâ€specific CSF proteins tau and amyloidâ€beta in Parkinsonian syndromes. Movement Disorders, 2010, 25, 1284-1288.	2.2	44
137	Etiology, Pathology, and Pathogenesis. Blue Books of Neurology, 2010, , 417-431.	0.1	0
138	Graded cutaneous electrical vs thermal stimulation in humans shows different insular and cingulate cortex activation. Somatosensory & Motor Research, 2010, 27, 15-27.	0.4	5
139	Observing Huntingtonâ€™s Disease: the European Huntingtonâ€™s Disease Networkâ€™s REGISTRY. PLOS Currents, 2010, 2, RRN1184.	1.4	124
140	Five siRNAs Targeting Three SNPs May Provide Therapy for Three-Quarters of Huntington's Disease Patients. Current Biology, 2009, 19, 774-778.	1.8	227
141	Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurology, The, 2009, 8, 791-801.	4.9	856
142	Cortical dysfunction in patients with Huntington's disease during working memory performance. Human Brain Mapping, 2009, 30, 327-339.	1.9	72
143	The gene coding for PGC-1Î± modifies age at onset in Huntington's Disease. Molecular Neurodegeneration, 2009, 4, 3.	4.4	119
144	A Europeâ€wide assessment of current medication choices in Huntington's disease. Movement Disorders, 2008, 23, 1788-1788.	2.2	40

#	Article	IF	Citations
145	Aberrant connectivity of lateral prefrontal networks in presymptomatic Huntington's disease. Experimental Neurology, 2008, 213, 137-144.	2.0	104
146	Impaired Regulation of Brain Mitochondria by Extramitochondrial Ca2+ in Transgenic Huntington Disease Rats. Journal of Biological Chemistry, 2008, 283, 30715-30724.	1.6	76
147	Dorsolateral prefrontal cortex dysfunction in presymptomatic Huntington's disease: evidence from event-related fMRI. Brain, 2007, 130, 2845-2857.	3.7	131
148	High-Capacity Adenoviral Vector-Mediated Reduction of Huntingtin Aggregate Load In Vitro and In Vivo. Human Gene Therapy, 2007, 18, 303-311.	1.4	52
149	Riluzole in Huntington's disease: a 3â€year, randomized controlled study. Annals of Neurology, 2007, 62, 262-272.	2.8	160
150	Cocaineâ€•and amphetamineâ€regulated transcript is increased in Huntington disease. Movement Disorders, 2007, 22, 1952-1954.	2.2	18
151	Myopathy as a first symptom of Huntington's disease in a Marathon runner. Movement Disorders, 2007, 22, 1637-1640.	2.2	86
152	Immunohistochemical analysis of KCNQ3 potassium channels in mouse brain. Neuroscience Letters, 2006, 400, 101-104.	1.0	54
153	Immunohistochemical analysis of KCNQ2 potassium channels in adult and developing mouse brain. Brain Research, 2006, 1077, 1-6.	1.1	52
154	Mitochondrial impairment in patients and asymptomatic mutation carriers of Huntington's disease. Movement Disorders, 2005, 20, 674-679.	2.2	162
155	Huntington's disease. , 2005, , 847-860.		2
156	Thalamic Atrophy in Huntington's Disease Co-varies with Cognitive Performance: A Morphometric MRI Analysis. Cerebral Cortex, 2005, 15, 846-853.	1.6	150
157	Improving binding potential analysis in [11C]raclopride PET studies using cluster analysis. Medical Physics, 2004, 31, 902-906.	1.6	6
158	Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 3498-3503.	3.3	666
159	Gabapentin-lactam, but not gabapentin, reduces protein aggregates and improves motor performance in a transgenic mouse model of Huntington?s disease. Naunyn-Schmiedeberg's Archives of Pharmacology, 2004, 370, 131-9.	1.4	14
160	Imaging of activated microglia with PET and [11 C]PK 11195 in corticobasal degeneration. Movement Disorders, 2004, 19, 817-821.	2.2	39
161	Global cerebral atrophy in early stages of HuntingtonÊ¼s disease: quantitative MRI study. NeuroReport, 2004, 15, 363-365.	0.6	67
162	Transgenic rat model of Huntington's disease. Human Molecular Genetics, 2003, 12, 617-624.	1.4	329

#	Article	IF	Citations
163	Proteases Acting on Mutant Huntingtin Generate Cleaved Products that Differentially Build Up Cytoplasmic and Nuclear Inclusions. Molecular Cell, 2002, 10, 259-269.	4.5	356
164	Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's disease. Movement Disorders, 2002, 17, 748-757.	2.2	108
165	Expression Analysis of Ataxinâ€7 mRNA and Protein in Human Brain: Evidence for a Widespread Distribution and Focal Protein Accumulation. Brain Pathology, 2000, 10, 385-394.	2.1	53
166	Localization of metabotropic glutamate receptor 7 mRNA and mGluR7a protein in the rat basal ganglia. , 1999, 415, 266-284.		138
167	An Isoform of Ataxinâ€3 Accumulates in the Nucleus of Neuronal Cells in Affected Brain Regions of SCA3 Patients. Brain Pathology, 1998, 8, 669-679.	2.1	189
168	Expression of N-Methyl-D-Aspartate receptor subunit mRNAs in the human brain: Striatum and globus pallidus. Journal of Comparative Neurology, 1998, 390, 63-74.	0.9	60
169	Expression of N-Methyl-D-Aspartate receptor subunit mRNAs in the human brain: Hippocampus and cortex. , 1998, 390, 75-90.		120
170	Expression of NMDAR2D glutamate receptor subunit mRNA in neurochemically identified interneurons in the rat neostriatum, neocortex and hippocampus. Molecular Brain Research, 1996, 42, 89-102.	2.5	161
171	Modulation of cortical acetylcholine release by serotonin: the role of substance P interneurons. Naunyn-Schmiedeberg's Archives of Pharmacology, 1996, 354, 618-26.	1.4	29
172	Huntington's disease gene: Regional and cellular expression in brain of normal and affected individuals. Annals of Neurology, 1995, 37, 218-230.	2.8	206
173	Differential expression of mGluR5 metabotropic glutamate receptor mRNA by rat striatal neurons. Journal of Comparative Neurology, 1995, 354, 241-252.	0.9	178
174	IT15 gene expression in fetal human brain. Brain Research, 1994, 659, 33-41.	1.1	23
175	Premotor Programming and Cortical Processing in the Cerebral Cortex. Brain, Behavior and Evolution, 1989, 33, 141-146.	0.9	8